Company Description
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors.
The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK‑targeting chimeric degradation activation compound active against wild‑type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.
It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
| Country | Cayman Islands |
| Founded | 2010 |
| IPO Date | Feb 3, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10,600 |
| CEO | John Oyler |
Contact Details
Address: 94 Solaris Avenue Camana Bay, KY1-1108 Cayman Islands | |
| Phone | 345-949-4123 |
| Website | beigene.com |
Stock Details
| Ticker Symbol | BGNE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| CIK Code | 0001651308 |
| CUSIP Number | 07725L102 |
| ISIN Number | US07725L1026 |
| Employer ID | 98-1209416 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John V. Oyler | Co-Founder, Executive Chairman and Chief Executive Officer |
| Dr. Xiaobin Wu Ph.D. | President and Chief Operating Officer |
| Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board and Non-Executive Director and Co-Founder |
| Chan Lee | General Counsel and Senior Vice President |
| Wang Lai Ph.D. | Global Head of Research & Development |
| Aaron Rosenberg | Chief Financial Officer and Principal Financial Officer |
| Titus B. Ball | Vice President and Chief Accounting Officer |
| Liza Heapes | Head of Investor Relations |
| Yang Ji | Chief Compliance Officer |
| Dr. Yan Qi | Senior Vice President and Head of Public Affairs - Greater China |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 10, 2024 | 144 | Filing |
| Dec 10, 2024 | 8-K | Current Report |
| Dec 9, 2024 | 144 | Filing |
| Dec 9, 2024 | 144 | Filing |
| Dec 4, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 2, 2024 | 144 | Filing |
| Nov 26, 2024 | 144 | Filing |
| Nov 26, 2024 | 144 | Filing |
| Nov 25, 2024 | 144 | Filing |